Results 151 to 160 of about 1,650 (186)

Prevalence and associations of quetiapine fumarate misuse among an Australian national city sample of people who regularly inject drugs

Addiction, 2014
Aims: To estimate the prevalence of self-reported misuse of the antipsychotic quetiapine fumarate (quetiapine) among a sample of urban Australian people who inject drugs (PWID), and correlates of reported misuse in health and social domains.
Raimondo Bruno, Lucy Burns, Amy Kirwan   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dosing and switching strategies for quetiapine fumarate

Clinical Therapeutics, 2002
The atypical antipsychotic agent quetiapine fumarate has demonstrated efficacy and tolerability in clinical trials in patients with chronic or subchronic exacerbations of schizophrenic symptoms.This review summarizes clinical trial data and other practical information regarding the initiation and routine administration of quetiapine.
Andrew J, Cutler, Jeffrey M, Goldstein, John A, Tumas   +2 more
openaire   +2 more sources

Identification and Characterization of Potential Impurities of Quetiapine Fumarate

Pharmaceutical Development and Technology, 2008
Seven potential impurities, including by-products, starting materials and intermediates were identified in pharmaceutical substance quetiapine fumarate and characterized by spectroscopic methods (MS, IR, NMR). Based on these methods the structures of the impurities were assigned or confirmed as: impurity I: 2-(phenylthio)aniline; impurity II: phenyl N-[
Elzbieta U, Stolarczyk, Lukasz, Kaczmarek, Kamil, Eksanow, Marek, Kubiszewski, Magdalena, Glice, Andrzej, Kutner   +5 more
openaire   +2 more sources

Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate

Die Pharmazie, 2008
In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05–0.15% by reverse-phase HPLC. These impurities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,
Ch, Bharathi, K J, Prabahar, Ch S, Prasad, M, Srinivasa Rao, G N, Trinadhachary, V K, Handa, R, Dandala, A, Naidu   +7 more
openaire   +3 more sources

Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
This 10-day, single-center, open-label, randomized, crossover study compared pharmacokinetic profiles and tolerability of extended release quetiapine fumarate (quetiapine XR) with quetiapine immediate release (quetiapine IR) in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
Carlos, Figueroa, Martin, Brecher, Jennifer E, Hamer-Maansson, Helen, Winter   +3 more
openaire   +2 more sources

Tolerability of extended‐release quetiapine fumarate compared with immediate‐release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double‐blind, parallel‐group study

International Journal of Geriatric Psychiatry, 2012
: Objective The objective of this study was to assess the safety and tolerability of extended-release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate-release (quetiapine IR) in older patients with Alzheimer's disease with symptoms ...
Peter Paul De Deyn, Hans Eriksson
exaly   +1 more source

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

Current Medical Research and Opinion, 2013
A series of studies were conducted to guide the development and characterise the pharmacokinetics of extended-release quetiapine fumarate (quetiapine XR), a once-daily formulation to control the release of the drug.Data from these studies are described and discussed herein.Once-daily quetiapine XR produced a similar area under the plasma concentration ...
Khanh, Bui, Willie, Earley, Svante, Nyberg   +2 more
openaire   +2 more sources

Quetiapine fumarate (Seroquel(R)): A new atypical antipsychotic

Drugs of Today, 1999
The goal of antipsychotic drug development efforts over the past 10 years has been to develop agents with increased efficacy and safety and fewer of the side effects commonly associated with the older antipsychotic medications. The newer agents, often called atypical antipsychotics, are effective in treating both the positive and negative symptoms of ...
openaire   +2 more sources

Quetiapine fumarate overdose: Clinical and pharmacokinetic lessons from extreme conditions

Clinical Pharmacology & Therapeutics, 2000
Although the new atypical antipsychotic, quetiapine fumarate, is growing in popularity over its progenitor, clozapine, clinical experience with overdose of this agent remains limited. Observation of an overdose situation provided a unique opportunity to define the safety, clinical effects, and pharmacokinetics of this medication more clearly.A patient ...
P T, Pollak, K, Zbuk
openaire   +2 more sources

Pharmacokinetics, Tolerability, and Clinical Effectiveness of Quetiapine Fumarate

The Journal of Clinical Psychiatry, 2000
This is the first investigation of the pharmacokinetics, tolerability, and efficacy of quetiapine fumarate in adolescents with chronic or intermittent psychotic disorders.Ten patients with DSM-IV chronic or intermittent psychotic disorders (ages 12.3 through 15.9 years) participated in an open-label, rising-dose trial and received oral doses of ...
B J, McConville, L A, Arvanitis, P T, Thyrum, C, Yeh, L A, Wilkinson, R O, Chaney, K D, Foster, M T, Sorter, L M, Friedman, K L, Brown, J E, Heubi   +10 more
openaire   +2 more sources